96 results about "Pancreatitides" patented technology

The invention discloses an acute pancreatitis complication assessment method based on artificial intelligence, and belongs to the technical field of medical information, and the method specifically comprises the steps: firstly, obtaining a clinical data set containing real-time clinical indexes and basic disease historical records; performing time sequence analysis on the historical records of the basic diseases, extracting long-term influence characteristics of the historical records of the basic diseases and generating basic disease influence factors; carrying out standardization processing on the real-time clinical indexes and the basic disease influence factors, and generating a comprehensive feature vector after calculating association weights among features; inputting the vector into a trained artificial intelligence evaluation model, and outputting a complication risk probability through layer-by-layer nonlinear transformation; and finally, mapping the risk probability value into a risk level, and integrating patient information to generate a structured risk assessment report. And an acute pancreatitis complication evaluation scheme integrating the acute stage index and the chronic basic disease influence is established.

The invention provides an Akkermann Amuc1100 protein mutant as well as a preparation method and application thereof, wild Akkermann Amuc1100 protein is subjected to mutation modification through a molecular biological technical means, and the bioactivity of the Amuc1100 protein mutant subjected to molecular modification is obviously improved compared with that of the wild protein; compared with a wild type Amuc1100 protein, the wild type Amuc1100 protein has a better effect when being applied to the aspects of regulating intestinal immunity, relieving acute pancreatitis, promoting browning of white adipose cells, inhibiting obesity, relieving ulcerative colitis and the like, and a very good application prospect is provided for developing bioactive medicines with higher efficiency.

The invention relates to an oxidase response type molecular probe as well as a preparation method and application thereof, and belongs to the technical field of medical imaging. Aiming at the problem that the inflammation activity is difficult to accurately evaluate in the prior art, the invention provides a molecular imaging probe capable of responding to the activity of in-vivo myeloperoxidase (MPO), and the molecular imaging probe can be used for real-time and non-invasive imaging monitoring of the activity of the in-vivo MPO, so that the activity of the inflammatory reaction of a focus is accurately evaluated. The invention provides a chelating agent with structural characteristics of a chelating unit and an enzyme response unit, and is characterized in that the enzyme response molecular probe is constructed by taking rigid framework cyclohexanediamine (CDTA) as a transition metal chelating unit and taking electron-rich functional groups (such as phenol, catechol or 5-hydroxytryptamine) as the enzyme response unit. The probe is chelated with paramagnetic metal (such as Mn < 2 + >) for magnetic resonance imaging (MRI) or radioactive metal (such as 68Ga) for positron emission tomography (PET), so that specific response to MPO activity is realized. The dynamic stability of the probe is remarkably improved; after the MPO is responded, the relaxation efficiency is improved by 2-3 times, and the sensitivity is optimized; the cytotoxicity is low; in an acute pancreatitis model, the MRI contrast noise ratio (delta CNR) reaches 77.39 + / -7.04 and is 4.2 times that of a control group, the PET uptake rate is remarkably improved, bimodal imaging is supported, and accurate positioning and quantitative evaluation of the inflammation activity are achieved.

The invention belongs to the technical field of medicines, and provides application of a natural-source compound monomer medicine composition in preparation of medicines for preventing and / or treating pancreatitis. The pharmaceutical composition comprises baicalin, paeoniflorin, geniposide, wogonin, baicalein, albiflorin, tetrahydropalmatine, rhein, wogonin, aloe-emodin, saikoside A, emodin, benzoyl paeoniflorin, chlorogenic acid, costunolide, or a pharmaceutically acceptable salt thereof. Compared with the prior art, the pharmaceutical composition disclosed by the invention has the advantages that the components of the composition are definite and are all natural sources, the safety is good, the pharmaceutical effect has a remarkable synergistic effect, the administration dosage is reduced by about 200 times under the condition that the treatment effect is better than that of a compound traditional Chinese medicine, the administration mode of the compound medicine for treating pancreatitis is innovated, and the pharmaceutical composition is suitable for clinical application. A new scheme is provided for the treatment of the disease.

The invention relates to the technical field of medical biology, in particular to a chronic pancreatitis complication risk grading system based on exosome transcriptome data, and aims to solve the problems that existing chronic pancreatitis (CP) typing lacks molecular basis, complication risk prediction is weak and clinical transformation is poor. According to the system, plasma exosomes are extracted and sequenced, a functional characteristic gene set is constructed in combination with pancreas single cell data, CP is divided into three risk increasing subtypes by using a COCA algorithm, and finally 12 core miRNAs are screened to construct a BPNN diagnosis model. The invention proves that the plasma exosome can be used for staging classification of chronic pancreatitis for the first time, miRNA non-invasive accurate layering illness conditions can be detected through qPCR, the risk of fatty diarrhea and 3c type diabetes mellitus can be predicted, and the non-invasiveness, convenience, classification accuracy and result repeatability of the plasma exosome have clinical application and transformation advantages.

The application belongs to the technical field of medicine, and relates to a compound composition, a preparation method and application, in particular to a compound sodium salicylate composition for treating acute pancreatitis and a preparation method. The compound sodium salicylate composition comprises quercetin, diammonium glycyrrhizinate and sodium salicylate, wherein the mass ratio of quercetin, diammonium glycyrrhizinate and sodium salicylate is 1-5:5-20:50-200. When the compound sodium salicylate composition is an injection, it comprises quercetin, diammonium glycyrrhizinate, sodium salicylate, 1,2-propanediol, sodium bisulfite, dimethyl sulfoxide and 0.9% sodium chloride injection. The volume ratio of 1,2-propanediol and dimethyl sulfoxide in the injection is 14-20% and 0.25-1% respectively; and the mass / volume ratio of sodium bisulfite in the injection is 0.1-0.3%. The compound sodium salicylate composition can significantly reduce amylase, lipase, IL-6 and IL-1beta, and can be used for preparing a medicine for treating pancreatitis.

The invention discloses a dynamic diet risk assessment method and query system for pancreatitis, and the method comprises the steps: carrying out the multi-source heterogeneous collaborative analysis of feedback data collected by a mobile terminal and hospital discharge guide data through employing a distributed database cluster architecture, and constructing a dynamic risk prediction model based on a Spark Streaming real-time calculation engine and an LSTM neural network. And generating taboo period suggestions and risk compensation coefficients by quantitatively processing time sequence interaction association characteristics among the discharge days, the eating response types and the individual health parameters, and designing a closed-loop feedback mechanism to drive dynamic iterative optimization of the model. According to the system, automatic synchronization of user feedback data and a database cluster is achieved through a Kafka message queue, cooperative processing of MongoDB document rules and Redis real-time sorting is achieved depending on a differential storage engine, and personalized diet risk quantitative evaluation for dynamic changes of pancreatitis patients in the rehabilitation stage is achieved. The taboo period prediction accuracy is improved, the recurrence risk is reduced, and the generalization ability of the system is continuously optimized through a sliding window triggering mechanism.

The invention provides a marker combination for predicting severe acute pancreatitis and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of a risk marker for judging severe acute pancreatitis or a detection reagent of the gene, the mRNA, the cDNA and the protein, and the gene, the mRNA, the cDNA and the protein are used for preparing / establishing a diagnostic reagent or a kit / equipment for judging the occurrence risk of severe acute pancreatitis. Researches show that the severe acute pancreatitis risk marker can be used as a marker for early judgment of whether acute pancreatitis patients develop into severe acute pancreatitis, has high sensitivity and specificity, can quickly diagnose severe acute pancreatitis at a relatively early disease progress stage, and provides powerful assistance for early treatment intervention of diseases.

The invention discloses an external application medicine formula for acute pancreatitis, and belongs to the field of traditional Chinese medicine preparation formulas, and the external application medicine formula for acute pancreatitis is prepared from the following raw materials in parts by weight: 1-2 parts of honeysuckle, 1-2 parts of wild chrysanthemum flower, 1-2 parts of dandelion, 1-2 parts of herba violae, 1 part of scutellaria baicalensis, 1 part of coptis chinensis, 1 part of raw rhubarb, 1 part of raw liquorice, 1 part of radix paeoniae rubra and 1 part of mangnolia officinalis. The traditional Chinese medicine composition can effectively reduce peripancreatic exudation and promote gastrointestinal motility, so that the symptoms of abdominal distension and abdominal pain of a patient are relieved, meanwhile, pancreatic microcirculation can be improved, disease recovery is facilitated, the preparation process is simple and easy to understand, complex equipment is not needed, and the production cost is greatly reduced.

The invention relates to the technical field of novel application of compounds, in particular to novel application of meclozine and analogues thereof. The invention relates to an application of at least one of meclozine and analogues thereof or pharmaceutically acceptable salts or esters thereof in preparation of drugs for preventing and / or treating pancreatitis. The meclozine and the analogue thereof can obviously improve pancreatic tissue necrosis, inflammatory response and oxidative stress of pancreatitis, inhibit alveolar cell death and improve lung injury caused by pancreatitis, so that the meclozine and the analogue thereof can be used as a medicine for treating pancreatitis.

The invention discloses a si-TGM2-loaded macrophage targeting nano-material as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims at solving the problem that a macrophage targeting nano-drug for inhibiting severe acute pancreatitis aiming at a TGM2 target is lacked in the prior art. The technical key points of the invention are as follows: the si-TGM2-loaded macrophage targeting nano material is provided, the si-TGM2-loaded macrophage targeting nano material is a lactoferrin modified cationic lipid nucleic acid drug, and the cationic lipid nucleic acid drug is prepared by coating si-TGM2 as shown in SEQ.ID. NO.1 with a cationic liposome. The si-TGM2-loaded macrophage targeting nanometer material disclosed by the invention has a wide application prospect in preparation of an acute pancreatitis diagnostic kit and a medicine.

The utility model provides a canine pancreatitis detection card storage box, belongs to the technical field of detection card storage, and aims to solve the problem that the shading effect on detection cards is affected as the detection cards on the uppermost layer are in contact with light when the detection cards are taken and placed. Comprising a heat preservation storage box body, a limiting drawer, a limiting supporting plate, a heat preservation sealing cover, a position limiting piece, a limiting pressing plate and a positioning pressed piece. The limiting drawer is connected to the lower portion of the heat preservation storage box body in a sliding mode. The limiting supporting plate is hinged to the right side of the limiting drawer; the heat preservation sealing cover is clamped at the upper part of the heat preservation storage box body; the position limiting piece is fixedly connected to the upper portion of the heat preservation sealing cover. The limiting pressing plate is located on the lower portion of the heat preservation sealing cover. The positioning pressed parts are connected to the front side and the rear side of the heat preservation sealing cover in a sliding mode; according to the storage box, the shading effect on the detection card is ensured, the accuracy and the reliability of a detection result are ensured, and the use effect of the storage box is improved.

The invention discloses an acute necrotizing pancreatitis severe prediction model construction method based on a machine learning method. The acute necrotizing pancreatitis severe prediction model construction method comprises the following steps: S1, collecting patient data based on an inclusion standard and an exclusion standard; s2, data preprocessing and feature selection; s3, obtaining an optimal differential diagnosis prediction model in combination with radiomics characteristics and a plurality of machine learning algorithms; s4, obtaining an evaluation index through prediction performance comparison; and S5, constructing a pancreas model, a pancreas surrounding model and a combination model, and producing an ROC curve interpretation result. The present invention develops and verifies a machine learning model for distinguishing between severe and moderate ANPs (i.e., ANSP and ANMSP). These models will be based on radiomics features extracted from pancreatic parenchyma portal vein phase CECT images, peripancreatic necrotic lesions, and combinations thereof. By evaluating the diagnostic performance of the models, early recognition of disease severity is realized, and support is provided for clinical decisions related to treatment.

The invention relates to an anti-S100A8 / A9 monoclonal antibody for treating severe acute pancreatitis and application of the anti-S100A8 / A9 monoclonal antibody. Specifically, the invention provides a nano antibody combined with dimers of S100A8 and S100A9 or an antigen binding fragment of the nano antibody, and provides application of the nano antibody or the antigen binding fragment in treatment of pancreatitis. Meanwhile, the invention also provides an application of the antibody combined with the dimers of the S100A8 and the S100A9 or the antigen binding fragment of the antibody in treatment of pancreatitis. The antibody provided by the invention has a good treatment effect on severe acute pancreatitis, and has important clinical significance and development value.

1. Name of the product in this design: Playing cards (Diet for patients with hyperlipidemia and pancreatitis). 2. Purpose of this design: For use in playing card entertainment products. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design highlights: Component 1 main view. 5. The design for which protection is sought includes color. 6. This design is for a thin product, and the left, right, top, and bottom views of components 1 to 54 are omitted.

Disclosed herein are compositions and methods for improving pancreatitis through pharmacological manipulation of calcium signaling. Such compositions and methods can be used to improve symptoms of acute or chronic pancreatitis or to reduce the likelihood or severity of pancreatitis in individuals at risk for the condition. In other embodiments, disclosed herein are compositions and methods for improving viral disease through pharmacological manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods for improving Thl7-induced disease through pharmacological manipulation of calcium signaling.

Disclosed are a composition for preventing and / or treating pancreatitis and a method of preventing and / or treating pancreatitis. The composition includes an arylethylene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient. Also disclosed is the use of the arylethylene compound, the pharmaceutically acceptable salt thereof, or the solvate thereof in the manufacture of a medicament for preventing and / or treating pancreatitis in a patient or for treating one or more symptoms of pancreatitis in a patient. The method includes administering to a subject in need thereof an effective amount of the arylethylene compound, an isomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof.

The invention relates to an autoimmune pancreatitis treatment response evaluation system based on sequence image change. The system comprises the following steps: preprocessing a CT pancreatic image and an MRI pancreatic image to obtain preprocessed pancreatic image data; extracting multi-scale features of the preprocessed pancreatic image data; fusing and reconstructing the CT pancreatic image and the MRI pancreatic image by using the multi-scale features to obtain a fused feature image; and inputting the fused feature image as a training sample into a deep learning model for training to obtain a pancreatitis treatment response evaluation model so as to complete prediction of the treatment response of the target pancreatitis patient. According to the method, image data of CT and MRI in two different modes are combined, the defects of a single image mode can be overcome, more comprehensive and accurate focus information can be provided, the lesion area of the pancreas can be better presented after the CT and the MRI are combined, and especially in dynamic observation of lump changes in the treatment process, the pancreatic lesion area can be more accurately observed. And the reaction condition of pancreatitis can be evaluated more accurately.

The application discloses application of an HTRA1 inhibitor in preparation of a drug for treating pancreatitis-cancer transformation, and belongs to the technical field of medicines.The HTRA1 inhibitor is screened through a drug database, the HTRA1 inhibitor is used to treat a pancreatic cancer cell line and a mouse pancreatitis-cancer transformation in-vivo model, it is proved that the HTRA1 inhibitor Carfilzomib can inhibit the malignant phenotype of Panc1 cells in vitro, and can inhibit the transformation of a KC mouse stimulated by cerulean into a pancreatic ductal adenocarcinoma in vivo, and the application provides a basis for using the HTRA1 inhibitor as the drug for treating pancreatitis-cancer transformation.

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and / or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

Aspects of the present application provide dual inhibitor antitrypsin 1 / trypsin 2 antibodies and methods of using the antibodies to treat pancreatitis.

The invention provides a rheum officinale active ingredient composition as well as a preparation method and application thereof, and the active ingredients of the composition consist of emodin methyl ether glycoside, rhein, rhein, gallic acid, emodin and chrysophanol glycoside. The weight ratio of physcion glycoside to rhein glycoside to rhein to gallic acid to emodin to chrysophanol glycoside is 200: 100: 20: 10: 1: 1, the composition is prepared in a monomer mixing mode, the pancreatitis focus area is remarkably reduced, the pathological score is remarkably improved, and the serum amylase and lipase level is remarkably reduced; a certain liver protection effect is achieved; the components are clear in material basis, have no obvious liver and kidney toxicity, and can obviously improve and treat pancreatitis.

This invention discloses the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating acute respiratory distress syndrome (ARDS) induced by severe acute pancreatitis, belonging to the field of nanomedicine technology. This invention is the first to propose the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating ARDS induced by severe acute pancreatitis, providing a new method for treating ARDS and expanding the application of rhubarb-derived exosome-like nanovesicles in the pharmaceutical field. This invention is also the first to propose using rhubarb-derived exosome-like nanovesicles as the active ingredient in a pharmaceutical composition for treating ARDS induced by severe acute pancreatitis.

Described herein are methods and compositions relating to inhibition of bile salt hydrolase (BSH) and uses thereof. Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (e.g., gastrointestinal infections; inflammatory bowel disease (IBD); appendicitis; crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; a liver disease (e.g., non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis), gastroesophageal reflux disease (GERD); celiac disease; diverticulosis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; intestinal leakage; the present invention relates to a method for treating a cancer (e.g., digestive cancer, liver cancer), a cancer (e.g., digestive cancer, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis). The method comprises administering to the subject a compound of Formula (I)-(XVIII).

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

The invention provides application of an antibacterial peptide in preparation of a medicine for treating, preventing or relieving pancreatic diseases or related intestinal diseases caused by the pancreatic diseases. The antibacterial peptide comprises REG3B, LL-37 and RNASE1 (Ribonucleic Acid SE1), has a treatment effect on pancreatitis and pancreatitis-mediated intestinal injury and inflammation, and can regulate pancreas-intestine interaction.